Strand Life Sciences

ReadSense, a company engaged in genome research at the Technospark nano-center in Troitsk, and India’s Strand Life Sciences have signed a memorandum of cooperation under which they will join efforts to develop affordable next-generation sequencing (NGS) based tests to diagnose genetic disorders, such as the heritable forms of epilepsy or primary immunodeficiency. Besides, Strand will share technology in the area of genome data analysis and bioinformatics, and will contribute a unique expertise in diagnostic business development in the US and India. As part of cooperation, ReadSense will conduct DNA tests of patients’ blood using Strand’s comprehensive solutions for interpreting test results. The areas selected for operations include neurology, gastroenterology and pulmonology.

28 June 2015

Investor profile

Strand Life Sciences


Company's website:

T: +91-80-40-STRAND (787263)

Private company


Contact: VIJAY CHANDRU, PhD Co-Founder, President and CEO

Strand Life Sciences is an innovative healthcare company specializing in solutions combining the latest scientific discoveries with visualization and modeling to conduct biological research. Over 2,000 scientific laboratories across the world (around 30% of the global market) license technology from Strand Life Sciences. Three clinical research labs opened by the company in the Indian state of Bangalore use the latest NGS technology. By implementing molecular genetic diagnostics and interpretation of clinical and genome data with the help of experts in IT, medicine and science, Strand Life Sciences has become a leading innovator in the field of personalized medicine.